Traditional EGFR inhibitors like gefitinib, erlotinib, and osimertinib have achieved significant efficacy in EGFR‐mutated NSCLC patients but inevitably develop acquired resistance, mainly caused by secondary mutations like T790M and C797S [378]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.